Aceclofenac/eperisone controlled-release - Navipharm

Drug Profile

Aceclofenac/eperisone controlled-release - Navipharm

Alternative Names: Aceclofenac/eperisone SR; Eperisone controlled-release/aceclofenac; Eperisone SR/aceclofenac; NVP-1203

Latest Information Update: 06 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Navipharm
  • Class Esters; Muscle relaxants; Neuroprotectants; Nonsteroidal anti-inflammatories; Phenylacetates; Piperidines; Propiophenones; Small molecules
  • Mechanism of Action Calcium channel antagonists; Cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Back pain

Most Recent Events

  • 31 Jan 2018 Phase-II clinical trials in Back pain in South Korea (PO) (NCT03341832)
  • 28 Jan 2018 No recent reports of development identified for phase-I development in Back-pain(In volunteers) in South Korea (PO)
  • 17 Nov 2017 Navipharm Corporation plans a phase II trial for Back pain in South Korea in January 2018 (NCT03341832)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top